Faculty profile

Yu Wang

ResearcherMedicine/NeurologyUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.

Yu Wang

Researcher

Medicine/Neurology

Health Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
7 publications in the last five years, latest in 2025.
Principal investigator on 7 research grants (7 CIHR), most recently in 2023.
Supervised 1 trainee who won CIHR awards, most recently in 2011.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Brain Slices Cell Biology Electrophysiology Cultured Neurons Receptor Trafficking Epilepsy Gaba-A Receptor Synaptic Plasticity

Latest papers

Longitudinal single-cell analysis reveals RUNX1T1 as an early driver in treatment-induced neuroendocrine transdifferentiation.
bioRxiv : the preprint server for biology · 2025
Deciphering the Transcription Factor Landscape in Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025 · first author
Identification of the specific characteristics of neuroendocrine prostate cancer: Immune status, hub genes and treatment.
Translational oncology · 2025

All 11 publications

Latest funding

Physiological and pathological regulation of GABAA receptor functions
CIHR · 2023 · Nominated PI
$944,776
Regulation of postsynaptic expression and function of ionotropic neurotransmitter receptors
CIHR · 2016 · Nominated PI
$5,023,651
Developing novel GluN2A-containing NMDAR-based stroke therapies
CIHR · 2016 · Nominated PI
$955,625

All 11 grants and awards

11 publications.

Longitudinal single-cell analysis reveals RUNX1T1 as an early driver in treatment-induced neuroendocrine transdifferentiation.

Ni Y, Lin D, Shi M, Lin YY, Xue H, Dong X, Liu L, Sar F, Wu R, Morova T, Haegert A, Bell R, Pang X, Classen A, Wang Y, Chen J, Volik S, Bihan SL, Lack N, Ong C, Wang G, Zeng H, Collins C, Wang Y

bioRxiv : the preprint server for biology2025

DOI: 10.1101/2025.05.14.653660 PMID: 40463134

Deciphering the Transcription Factor Landscape in Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation.

Wang Y, Xue H, Zhu X, Lin D, Chen Z, Dong X, Chen J, Shi M, Ni Y, Cao J, Wu R, Kang C, Pang X, Crea F, Lin YY, Collins CC, Gleave ME, Parolia A, Chinnaiyan A, Ong CJ, Wang Y

Advanced science (Weinheim, Baden-Wurttemberg, Germany)2025First author

DOI: 10.1002/advs.202404938 PMID: 40091506

Identification of the specific characteristics of neuroendocrine prostate cancer: Immune status, hub genes and treatment.

Wang J, Wang Y, Zhou H, Yu G, Xu H, Gao D, Li M, Wang Y, Xu B

Translational oncology2025

DOI: 10.1016/j.tranon.2025.102320 PMID: 39999729

Transcription Factor Dynamics in Neuroendocrine Prostate Cancer Development.

Wang Y, Wang Y

Holistic integrative oncology.2025First author

DOI: 10.1007/s44178-025-00197-x PMID: 41142932

The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions.

Wang Y, Scurll J, Rascón IA, Cui C, Ni Y, Shi AM, Gangadharannambiar P, Wang Y, Akamatsu S, Beltran H, Cox M, Crea F, Daugaard M, Dong X, Haffner M, He H, Jachetti E, Kyprianou N, Li B, Ong CE, Rickman DS, Sen T, Zhu HH, Zoubeidi A, Gleave ME

Epigenomics2024

DOI: 10.1080/17501911.2024.2391729 PMID: 39225130

Genomic alterations in neuroendocrine prostate cancer: A systematic review and meta-analysis.

Chen J, Shi M, Chuen Choi SY, Wang Y, Lin D, Zeng H, Wang Y

BJUI compass2023

DOI: 10.1002/bco2.212 PMID: 37025467

Patient-derived xenograft models of neuroendocrine prostate cancer.

Shi M, Wang Y, Lin D, Wang Y

Cancer letters2022

DOI: 10.1016/j.canlet.2021.11.004 PMID: 34767925

Molecular events in neuroendocrine prostate cancer development.

Wang Y, Wang Y, Ci X, Choi SYC, Crea F, Lin D, Wang Y

Nature reviews. Urology2021

DOI: 10.1038/s41585-021-00490-0 PMID: 34290447

ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development.

He H, Hao J, Dong X, Wang Y, Xue H, Qu S, Choi SYC, Ci X, Wang Y, Wu R, Shi M, Zhao X, Collins C, Lin D, Wang Y

Prostate cancer and prostatic diseases2021

DOI: 10.1038/s41391-021-00322-7 PMID: 33568749

Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.

Hao J, Ci X, Xue H, Wu R, Dong X, Choi SYC, He H, Wang Y, Zhang F, Qu S, Zhang F, Haegert AM, Gout PW, Zoubeidi A, Collins C, Gleave ME, Lin D, Wang Y

European urology2018

DOI: 10.1016/j.eururo.2018.02.019 PMID: 29544736

Something wrong or missing on this profile? Suggest a correction

Yu Wang

Research

Latest papers

Latest funding

Longitudinal single-cell analysis reveals RUNX1T1 as an early driver in treatment-induced neuroendocrine transdifferentiation.

Deciphering the Transcription Factor Landscape in Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation.

Identification of the specific characteristics of neuroendocrine prostate cancer: Immune status, hub genes and treatment.

Transcription Factor Dynamics in Neuroendocrine Prostate Cancer Development.

The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions.

Genomic alterations in neuroendocrine prostate cancer: A systematic review and meta-analysis.

Patient-derived xenograft models of neuroendocrine prostate cancer.

Molecular events in neuroendocrine prostate cancer development.

ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development.

Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.

Physiological and pathological regulation of GABAA receptor functions

Regulation of postsynaptic expression and function of ionotropic neurotransmitter receptors

Developing novel GluN2A-containing NMDAR-based stroke therapies

Regulation of postsynaptic expression and function of GABA-A receptors

Canadian Stroke Network (2006 Renewal Competition)

Investigation into the molecular mechanisms of AMPAR trafficking following primary blast-induced mTBI

Investigation into molecular mechanisms and physiological roles of activity-dependent AMPAR trafficking

Role of PTEN nuclear translocation in NMDAR-mediated exciotoxic neuronal death in Huntington's Disease

Investigation into the molecular mechanisms mediating excitotoxicity - developing novel post-stroke therapies

From Down Syndrome to Alzheimer's Disease: the molecular mechanism underlying the dementia pathogenesis and the therapeutic potentials

Frequent collaborators

Yuzhuo Wang

Colin Collins

Amina Zoubeidi

Michael Cox

Mads Daugaard

Xuesen Dong

Gang Wang

Christopher Ong

Nathan Lack